Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Checkpoint – March 2025 | Ethereum Foundation Blog

    March 15, 2026

    SEC chair backs “minimum effective dose” disclosure and targeted tokenization pilots

    March 15, 2026

    Tom Lee’s ETH losses at Bitmine exceed FTX customer losses

    March 15, 2026
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram LinkedIn
    Ai Crypto TimesAi Crypto Times
    • Altcoins
      • Coinbase
      • Litecoin
      • Bitcoin
    • Ethereum
    • Crypto
    • Blockchain
    • Lithosphere News Releases
    Ai Crypto TimesAi Crypto Times
    Home » Tilray stock rallies as cannabis reclassification
    Crypto

    Tilray stock rallies as cannabis reclassification

    James WilsonBy James WilsonDecember 18, 2025No Comments3 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr Email
    Share
    Facebook Twitter LinkedIn Pinterest Email


    Tilray stock price continued its recent rally, reaching its highest point since October 20, ahead of the potential cannabis reclassification executive order by President Donald Trump. 

    Summary

    • Tilray Brands stock price rallied as Trump prepared to sign an executive order on cannabis reclassification.
    • That reclassification will move cannabis from a Schedule 1 drug to Schedule 3.
    • While the stock may keep rising, it faces more headwinds in the near term.

    Tilray Brands (TLRY), a leading company in the Cannabis industry, reached a high of $15.71. This surge brought its valuation to over $1.7 billion.

    As of the last check, it was trading at approximately $13.05 per share, up approximately 240% over the past six months.

    Trump has hinted that he will sign an executive order that will move cannabis classification from Schedule 1 to Schedule 3. That transition will make it easy for companies to sell cannabis and its products in the U.S.

    It will also help Tilray Brands establish a presence in the country, either organically or through acquisitions. Moreover, it has a strong balance sheet that may be leveraged to engineer a buyout. 

    Still, there are potential risks that may impact Tilray shares and those of other cannabis companies. First, Trump’s executive order will not automatically reschedule cannabis. Instead, it will have to undergo a lengthy process, including public comment. 

    Most importantly, it will likely face litigation, as opponents will likely sue. This is what derailed Joe Biden’s attempt to reclassify the product in his first term. 

    Second, the rescheduling will not address other challenges that cannabis companies face in the U.S. For example, companies in the industry will still face the banking challenges they have always had. This will only change when the Senate and House pass a cannabis bill. 

    Third, Tilray stock has jumped ahead of the rescheduling executive order. Therefore, it is likely to decline after the event, as investors sell the news and wait for the next catalyst. 

    Additionally, the company’s pivot to the beverage industry is not working out. In its recent report, TLRY said that the segment’s revenue dropped to $55.7 million from the $56 million it made in the same period last year. Its gross margin also declined to 38% from 41%.

    Tilray stock price technical analysis 

    tilray stock
    TLRY stock chart | Source: TradingView

    The daily chart shows that the TLRY stock price bottomed at $7 on Dec. 4 and has reached a high of $15.7 today. It rebounded after forming a falling wedge pattern, a bullish reversal sign. 

    It formed a bullish gap on Dec. 11 and has now moved above the 50-day and 100-day Exponential Moving Averages. It also rose above the 50% Fibonacci Retracement level. 

    The Relative Strength Index is nearing the overbought level at 70. Therefore, the stock price will likely continue to rise ahead of the rescheduling and then pull back after it occurs. If this happens, it may retreat to the support at $10.



    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    James Wilson

    Related Posts

    SEC chair backs “minimum effective dose” disclosure and targeted tokenization pilots

    March 15, 2026

    Aster price compresses within bullish wedge, $1.05 in focus

    March 15, 2026

    Playnance introduces G Coin as token economy for its blockchain gaming ecosystem

    March 15, 2026
    Leave A Reply Cancel Reply

    Our Picks
    Stay In Touch
    • Facebook
    • Twitter
    • Pinterest
    • Instagram
    • YouTube
    • Vimeo
    Don't Miss

    Checkpoint – March 2025 | Ethereum Foundation Blog

    Ethereum March 15, 2026

    Ethereum’s weekly All Core Developer calls are a lot to keep up with, so this…

    SEC chair backs “minimum effective dose” disclosure and targeted tokenization pilots

    March 15, 2026

    Tom Lee’s ETH losses at Bitmine exceed FTX customer losses

    March 15, 2026

    Ethereum Protocol Fellowship Cohort 5 Recap

    March 15, 2026

    Subscribe to Updates

    Get the latest creative news from SmartMag about art & design.

    X (Twitter) Instagram YouTube LinkedIn
    Our Picks

    CHART: Has Trump been good for TRON?

    November 19, 2025

    EOS founder Dan Larimer predicts biblical apocalypse next week

    November 27, 2025

    Institutional Investors Pour $619,000,000 Into Bitcoin and Crypto Assets in One Week: CoinShares

    March 14, 2026
    Recent Posts

    Checkpoint – March 2025 | Ethereum Foundation Blog

    March 15, 2026

    SEC chair backs “minimum effective dose” disclosure and targeted tokenization pilots

    March 15, 2026

    Tom Lee’s ETH losses at Bitmine exceed FTX customer losses

    March 15, 2026

    Type above and press Enter to search. Press Esc to cancel.